PRGN-2009

AXP000160.1 · Cancer vaccine

Platform
gorilla adenovirus (AdenoVerse, non-replicating)
Originator
Precigen
Sponsor
Precigen

Names

NameTypeSource
PRGN-2009preferred name, codecurator, ncit
Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine ambiguoussynonymncit

Virus

Role
Vaccine vector
Family
Adenoviridae
Virus
gorilla adenovirus
Replication
non replicating
Modifications
non-replicating gorilla adenovirus vector (AdenoVerse platform)
Transgenes
HPV-16 and HPV-18 E6 and E7
Route
subcutaneous
Source
evidence

Cross-references

NCI Thesaurus
C172914

Approvals

No regulatory approval recorded.

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06157151PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerRecruitingPhase 22025-11-112026-11-1124Cervical Cancer; HPV-Related Carcinoma; HPV-Related Malignancy; Metastatic Cervical Cancer; Recurrent Cervical Carcinoma
NCT06223568Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerRecruitingPhase 22024-06-102028-01-1070Cancer Vaccine; Drug Therapy; Human Papillomavirus Viruses; Oropharynx; Squamous Cell Carcinoma of the Head and Neck
NCT05996523Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal CancerActive not recruitingPhase 22023-11-072025-05-2226Oropharyngeal Squamous Cell Carcinoma (SCC)
NCT04432597HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated CancersCompletedPhase 1/22020-08-112022-11-2239Anal Cancer; Cervical Cancer; HPV Positive Cancer; Oropharyngeal Cancer; Vulvar, Vaginal, Penile, Rectal Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40116923PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer.Cancer immunology, immunotherapy : CII2025cited by trial NCT04432597

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 33651712Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009.JCI insight2021name in title: PRGN-2009

NIH grants

ProjectTitleOrganisationPIYearsLinked by
ZIABC010598Human Immune Responses to Tumor Antigens for Cancer ImmunotherapyDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2012–2025name in abstract: PRGN-2009
ZIDDC000075NIDCD Core for Clinical Research and CareNATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSLEVY, JOSHUA2021–2025name in abstract: PRGN-2009
ZIABC010944Strategies for Cancer Immunotherapy Development: Preclinical StudiesDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2011–2024name in abstract: PRGN-2009

Notes

Gorilla adenovirus expressing HPV-16 and HPV-18 E6/E7 antigens with multiple cytotoxic T-cell epitopes; phase 1/2 in HPV-associated cancers, including with bintrafusp alfa and in recurrent oropharyngeal cancer. Separate construct from PRGN-2012 (AXP000159), which carries HPV 6/11.

How to cite

PRGN-2009 (AXP000160.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000160.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.